COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,160 Articles (22,703 medRxiv, 8,457 bioRxiv)

Most recent first Previous |  Page 741: Articles 7401-7410  | Next

α2,6-Sialylation is Upregulated in Severe COVID-19 Implicating the Complement Cascade
Qin, R., Kurz, E., Chen, S., Zeck, B., Chiriboga, L., Jackson, D., Herchen, A., Attia, T., Carlock, M. A., Rapkiewicz, A., Bar-Sagi, D., Ritchie, B., Ross, T. M., Mahal, L. K.
10.1101/2022.06.06.22275981 — Posted: 2022-06-08
Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity
Yoshiji, S., Butler-Laporte, G., Lu, T., Willett, J. D. S., Su, C.-Y., Nakanishi, T., Morrison, D. R., Chen, Y., Liang, K., Hultström, M., Afrasiabi, Z., Lan, S., Duggan, N., DeLuca, C., Vaezi, M., Tselios, C., Xue, X., Bouab, M., Shi, F., Laurent, L., Munter, H. M., Afilalo, M., Afilalo, J., Mooser, V., Timpson, N. J., Zeberg, H. J., Zhou, S., Forgetta, V., Farjoun, Y., Richards, J. B.
10.1101/2022.06.06.22275997 — Posted: 2022-06-08
Workplace infection control measures and perceived organizational support during the COVID-19 pandemic in Japan: a prospective cohort study
MORI, T., Nagata, T., Ando, H., Hino, A., Tateishi, S., Tsuji, M., Matsugaki, R., Fujino, Y., Mori, K.
10.1101/2022.06.06.22275988 — Posted: 2022-06-08
Early Treatment of Favipiravir in COVID-19 Patients Without Pneumonia: A Multicentre, Open-Labelled, Randomized Control Study
Sirijatuphat, R., Manosuthi, W., Niyomnaitham, S., Owen, A., Copeland, K., Charoenpong, L., Rattanasompattikul, M., Mahasirimongkol, S., Chokephaibulkit, K.
10.1101/2022.06.06.22275902 — Posted: 2022-06-08
Forecasting hospital-level COVID-19 admissions using real-time mobility data
Klein, B., Zenteno, A. C., Joseph, D., Zahedi, M., Hu, M., Copenhaver, M., Kraemer, M. U. G., Chinazzi, M., Klompas, M., Vespignani, A., Scarpino, S. V., Salmasian, H.
10.1101/2022.06.06.22275840 — Posted: 2022-06-08
COVID-19 and per capita green tea consumption: update
Storozhuk, M.
10.1101/2022.06.06.22276060 — Posted: 2022-06-07
Evolution of long-term hybrid immunity in healthcare workers after different COVID-19 vaccination regimens: a longitudinal observational cohort study
Moore, S. C., Kronsteiner, B., Longet, S., Adele, S., Deeks, A. S., Liu, C., Dejnirattisai, W., Silva Reyes, L., Meardon, N., Faustini, S., Al-Taei, S., Tipton, T., Hering, L. M., Angyal, A., Brown, R., Nicols, A. R., Dobson, S. L., Supasa, P., Tuekprakhon, A., Cross, A., Tyerman, J. K., Hornsby, H., Grouneva, I., Plowright, M., Zhang, P., Newman, T. A. H., Nell, J. M., Abraham, P., Ali, M., Malone, T., Neale, I., Phillips, E., Wilson, J. D., Shields, A., Horner, E. C., Booth, L. H., Stafford, L., Bibi, S., Wootton, D. G., Mentzer, A. J., Conlon, C. P., Jeffery, K., Matthews, P. C., Pollard, A
10.1101/2022.06.06.22275865 — Posted: 2022-06-07
Nirmatrelvir Resistant SARS-CoV-2 Variants with High Fitness in Vitro
Zhou, Y., Gammeltoft, K. A., Ryberg, L. A., Pham, L. V., Fahnoe, U., Binderup, A., Hernandez, C. R. D., Offersgaard, A., Fernandez-Antunez, C., Peters, G. H. J., Ramirez, S., Bukh, J., Gottwein, J. M.
10.1101/2022.06.06.494921 — Posted: 2022-06-07
The substitutions L50F, E166A and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor in vitro and confer resistance to nirmatrelvir
Jochmans, D., Liu, C., Donckers, K., Stoycheva, A., Boland, S., Stevens, S. K., De Vita, C., Vanmechelen, B., Maes, P., Trüeb, B. S., Ebert, N., Thiel, V., De Jonghe, S., Vangeel, L., Bardiot, D., Jekle, A., Blatt, L. M., Beigelman, L., Symons, J. A., Raboisson, P., Chaltin, P., Marchand, A., Neyts, J., Deval, J., Vandyck, K.
10.1101/2022.06.07.495116 — Posted: 2022-06-07
Development of an Escape-resistant SARS CoV-2 Neutralizing Synthetic Nanobody
Dormeshkin, D., Shapira, M., Dubovik, S., Kavaleuski, A., Katsin, M., Migas, A., Meleshko, A., Semyonov, S.
10.1101/2022.06.07.495065 — Posted: 2022-06-07

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).